You are being redirected because this document is part of your ASTM Compass® subscription.
    This document is part of your ASTM Compass® subscription.

    If you are an ASTM Compass Subscriber and this document is part of your subscription, you can access it for free at ASTM Compass

    Biotechnology Facility Approval at the Local Level: The Cambridge, Massachusetts, Experience

    Published: 01 January 1990

      Format Pages Price  
    PDF (60K) 4 $25   ADD TO CART
    Complete Source PDF (2.3M) 155 $55   ADD TO CART

    Cite this document

    X Add email address send
      .RIS For RefWorks, EndNote, ProCite, Reference Manager, Zoteo, and many others.   .DOCX For Microsoft Word


    In 1976 the citizens of Cambridge, Massachusetts, were concerned that the construction and operation of a laboratory intended for research with recombinant DNA (rDNA) material would pose a threat to public health and safety. The mayor of Cambridge initiated public hearings on the issue, which led to the formation of a Cambridge Experimentation Review Board, made up primarily of lay citizens. After lengthy hearings the group recommended a city ordinance that made the National Institutes of Health (NIH) guidelines on recombinant DNA technology the law in Cambridge. A Cambridge Biohazards Committee (CBC) was created to monitor compliance by the universities with the NIH guidelines. Later a permit structure was introduced. Companies requesting permits follow an application process which includes presentations to the CBC, site visits of the laboratories by the CBC, and periodic reinspection. Siting in the city is in accordance with zoning regulations for light industry. Cooperation has been good. Twenty-four permits have now been issued for research and pilot facilities. There are no rDNA manufacturing facilities in the city of Cambridge because of its population density and the expense of land and buildings.


    bioprocessing, recombinant DNA technology regulations, biotechnology regulation, Cambridge (MA) biohazards ordinance

    Author Information:

    Chalfen, MH
    Commissioner of Health and Hospitals, City of Cambridge, MA

    Committee/Subcommittee: E48.01

    DOI: 10.1520/STP26080S